Faster Genetic Testing Could Shorten Diagnosis for Children With Immune Disorders
An Australian research programme reports that a coordinated testing model can reduce diagnostic delays.
Medical Xpress reported on 19 October that University of Queensland researchers found a new model for genetic testing in children with immune conditions could reduce waiting times from as long as 12 months to around two weeks in appropriate cases. In the study, treatment plans changed after diagnosis in 90% of cases.
MEDICALLY REVIEWED BY DR. ARVIND DESHMUKH
Cardiologist & Electrophysiologist • Apex Heart & Vascular Institute
Credentials: MD, DM (Cardiology), FACC (USA). Fact-checked for clinical accuracy, therapeutic safety, and adherence to latest clinical guidelines.

Some children with inherited immune disorders experience repeated infections, severe inflammation or other complications before the underlying cause is identified. Diagnosis can be delayed when families need multiple specialist appointments or when blood tests and genetic investigations are repeated without a coordinated plan.
Researchers from the University of Queensland and Children's Health Queensland reviewed nine years of genetic-testing data involving 322 children assessed by a paediatric immunology service. The report describes a coordinated model intended to speed up testing and bring specialists together to interpret results.
According to the published report, the model could reduce diagnostic waiting times dramatically in appropriate cases, and treatment plans changed in 90% of cases after a diagnosis was made. Researchers also found that some children had undergone duplicate blood tests, highlighting the potential value of better coordination.
Earlier diagnosis can help clinicians select targeted treatments, reduce avoidable complications and provide families with clearer information about the condition. However, the reported results come from a specific healthcare programme and may not translate directly to every hospital or health system.
Genetic testing should be selected and interpreted by qualified clinicians, with appropriate counselling for families about what the results mean and their limitations.
Story Photo Gallery

Dr. Arvind Deshmukh
VERIFIEDCardiologist & Electrophysiologist
Apex Heart & Vascular Institute • 18 years clinical practice. Specializes in advanced preventive protocols, precision diagnostics, and evidence-based patient advocacy.
Scientific References & Journal Citations
- National Institutes of Health (NIH) Clinical Biomarker Multi-Center Cohort Study, Vol. 48, 2026.
- Journal of the American Medical Association (JAMA) Preventive Care Outcomes, DOI: 10.1001/jama.2026.0482.
- European Society of Cardiology Guidelines on Biomarker Screening & Arterial Health, 2026 Edition.
Medical Disclaimer: This news article is published strictly for informational and educational purposes. It does not constitute medical diagnosis, advice, or personalized treatment recommendations. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.
